KlkEgfbp2 Inhibitors
KlkEgfbp2 inhibitors include a range of chemical compounds that target various signaling pathways and kinases, which indirectly lead to the suppression of KlkEgfbp2 functional activity. LY294002 and Wortmannin, both inhibitors of phosphoinositide 3-kinases (PI3K), reduce the activity of the PI3K/AKT signaling pathway, resulting in the decreased function of KlkEgfbp2, provided it is a downstream target of this pathway. Similarly, MEK inhibitors such as U0126 and PD98059 block the MAPK/ERK pathway, which could lead to lowered KlkEgfbp2 activity if it is modulated by this route. Inhibitors targeting stress-related kinases, such as SB203580, also play a role in decreasing the functional activity of KlkEgfbp2 by diminishing its potential stress-responsive modulation.
Furthermore, compounds like Rapamycin, which inhibits the mammalian target of rapamycin (mTOR), and tyrosine kinase inhibitors like Gefitinib and Lapatinib, which target EGFR and HER2/neu kinases, respectively, could lead to a reduction in KlkEgfbp2 activity through the suppression of growth factor signaling pathways. Sorafenib, with its ability to inhibit RAF kinases, and SP600125, a selective c-Jun N-terminal kinase (JNK) inhibitor, may also contribute to the indirect inhibition of KlkEgfbp2 by affecting the MAPK and JNK signaling cascades that KlkEgfbp2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 leads to the downregulation of the PI3K/AKT signaling pathway. KlkEgfbp2, being a downstream effector of this pathway, would experience reduced activity as a result of decreased AKT activation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A specific inhibitor of mitogen-activated protein kinase kinases (MEK1/2), U0126 prevents the activation of the extracellular signal-regulated kinases (ERK1/2) pathway. KlkEgfbp2, which can be influenced by the ERK1/2 pathway, would have diminished activity due to the lack of ERK1/2 signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound selectively inhibits p38 MAP kinase, which is involved in stress and inflammatory responses. By inhibiting this kinase, SB203580 could reduce the functional activity of KlkEgfbp2 if it is modulated by stress-responsive pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor, wortmannin results in the inhibition of the AKT pathway, similar to LY294002. The reduced AKT pathway activity would correlate with decreased activity of KlkEgfbp2 if it is part of the AKT signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
This inhibitor of the mammalian target of rapamycin (mTOR) can suppress the mTORC1 complex, which affects cell growth and proliferation signals. If KlkEgfbp2 is involved in these pathways, rapamycin would lead to its inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
As an inhibitor of MEK, PD98059 blocks the MAPK/ERK pathway upstream, preventing the activation of ERK1/2 and potentially decreasing KlkEgfbp2 activity if it is regulated by this signaling route. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib would decrease EGFR signaling. KlkEgfbp2, if modulated by EGFR activity, would be inhibited due to the reduction in downstream signaling. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
This compound is a dual inhibitor of EGFR and HER2/neu tyrosine kinases. By inhibiting these receptors, lapatinib could decrease KlkEgfbp2 activity if the protein is a downstream component of the signaling pathways initiated by these receptors. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor targeting RAF kinases as well as other receptors. Inhibition of these kinases leads to decreased signaling through the MAPK pathway, potentially inhibiting KlkEgfbp2 if it relies on this pathway for activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective inhibitor of c-Jun N-terminal kinase (JNK), SP600125 disrupts the JNK signaling pathway. Should KlkEgfbp2 be a downstream target of this pathway, its activity would be indirectly inhibited. | ||||||